nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

15.10.2021 | Original Article

Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma

verfasst von: Kui Cao, Mingdong Liu, Keru Ma, Xiangyu Jiang, Jianqun Ma, Jinhong Zhu

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

The tumor immune microenvironment plays essential roles in regulating inflammation, angiogenesis, immune modulation, and sensitivity to therapies. Here, we developed a powerful prognostic signature with immune-related lncRNAs (irlncRNAs) in lung adenocarcinoma (LUAD). We obtained differentially expressed irlncRNAs by intersecting the transcriptome dataset for The Cancer Genome Atlas (TCGA)-LUAD cohort and the ImmLnc database. A rank-based algorithm was applied to select top-ranking altered irlncRNA pairs for the model construction. We built a prognostic signature of 33 irlncRNA pairs comprising 40 unique irlncRNAs in the TCGA-LUAD cohort (training set). The immune signature significantly dichotomized LUAD patients into high- and low-risk groups regarding overall survival, which is likewise independently predictive of prognosis (hazard ratio = 3.580, 95% confidence interval = 2.451–5.229, P < 0.001). A nomogram with a C-index of 0.79 demonstrates the superior prognostic accuracy of the signature. The prognostic accuracy of the signature of 33 irlncRNA pairs was validated using the GSE31210 dataset (validation set) from the Gene Expression Omnibus database. Immune cell infiltration was calculated using ESTIMATE, CIBERSORT, and MCP-count methodologies. The low-risk group exhibited high immune cell infiltration, high mutation burden, high expression of CTLA4 and human leukocyte antigen genes, and low expression of mismatch repair genes, which predicted response to immunotherapy. Interestingly, pRRophetic analysis demonstrated that the high-risk group possessed reverse characteristics was sensitive to chemotherapy. The established immune signature shows marked clinical and translational potential for predicting prognosis, tumor immunogenicity, and therapeutic response in LUAD.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69:363–385. https://doi.org/10.3322/caac.21565CrossRefPubMed

Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37:2518–2527. https://doi.org/10.1200/JCO.19.00934CrossRefPubMedPubMedCentral

Wang KC, Chang HY (2011) Molecular mechanisms of long non-coding RNAs. Mol Cell 43:904–914. https://doi.org/10.1016/j.molcel.2011.08.018CrossRefPubMedPubMedCentral

Goodall GJ, Wickramasinghe VO (2020) RNA in cancer. Nat Rev Cancer. https://doi.org/10.1038/s41568-020-00306-0CrossRefPubMed

Chen YG, Satpathy AT, Chang HY (2017) Gene regulation in the immune system by long non-coding RNAs. Nat Immunol 18:962–972. https://doi.org/10.1038/ni.3771CrossRefPubMed

Krawczyk M, Emerson BM (2014) p50-associated COX-2 extragenic RNA (PACER) activates COX-2 gene expression by occluding repressive NF-kappaB complexes. Elife 3:e01776. https://doi.org/10.7554/eLife.01776CrossRefPubMedPubMedCentral

Ranzani V, Rossetti G, Panzeri I et al (2015) The long intergenic non-coding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat Immunol 16:318–325. https://doi.org/10.1038/ni.3093CrossRefPubMedPubMedCentral

Li Y, Jiang T, Zhou W et al (2020) Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers. Nat Commun 11:1000. https://doi.org/10.1038/s41467-020-14802-2CrossRefPubMedPubMedCentral

10.

Kim S, Lin CW, Tseng GC (2016) MetaKTSP: a meta-analytic top scoring pair method for robust cross-study validation of omics prediction analysis. Bioinformatics 32:1966–1973. https://doi.org/10.1093/bioinformatics/btw115CrossRefPubMedPubMedCentral

11.

Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X, Zeng W, Ma L, Xie J (2020) Immune-related lncRNA to construct novel signature and predict the immune landscape of human hepatocellular carcinoma. Mol Ther Nucleic Acids 22:937–947. https://doi.org/10.1016/j.omtn.2020.10.002CrossRefPubMedPubMedCentral

12.

Zhu J, Liu Y, Zhao M, Cao K, Ma J, Peng S (2021) Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer. Aging (Albany NY). https://doi.org/10.18632/aging.202408CrossRefPubMedCentral

13.

Liu Y, Wu L, Ao H, Zhao M, Leng X, Liu M, Ma J, Zhu J (2019) Prognostic implications of autophagy-associated gene signatures in non-small cell lung cancer. Aging (Albany NY) 11:11440–11462. https://doi.org/10.18632/aging.102544CrossRef

14.

Karakiewicz PI, Briganti A, Chun FK et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25:1316–1322. https://doi.org/10.1200/JCO.2006.06.1218CrossRefPubMed

15.

Okayama H, Kohno T, Ishii Y et al (2012) Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res 72:100–111. https://doi.org/10.1158/0008-5472.CAN-11-1403CrossRefPubMed

16.

Yoshihara K, Shahmoradgoli M, Martínez E et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612. https://doi.org/10.1038/ncomms3612CrossRefPubMed

17.

Becht E, Giraldo NA, Lacroix L et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17:218. https://doi.org/10.1186/s13059-016-1070-5CrossRefPubMedPubMedCentral

18.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243–259. https://doi.org/10.1007/978-1-4939-7493-1_12CrossRefPubMedPubMedCentral

19.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453–457. https://doi.org/10.1038/nmeth.3337CrossRefPubMedPubMedCentral

20.

Geeleher P, Cox N, Huang RS (2014) pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE 9:e107468. https://doi.org/10.1371/journal.pone.0107468CrossRefPubMedPubMedCentral

21.

Geeleher P, Cox NJ, Huang RS (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47. https://doi.org/10.1186/gb-2014-15-3-r47CrossRefPubMedPubMedCentral

22.

Heinaniemi M, Nykter M, Kramer R et al (2013) Gene-pair expression signatures reveal lineage control. Nat Methods 10:577–583. https://doi.org/10.1038/nmeth.2445CrossRefPubMedPubMedCentral

23.

Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3:1529–1537. https://doi.org/10.1001/jamaoncol.2017.1609CrossRefPubMedPubMedCentral

24.

Luchini C, Bibeau F, Ligtenberg MJL et al (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol Off J Eur Soc Med Oncol 30:1232–1243. https://doi.org/10.1093/annonc/mdz116CrossRef

25.

Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V (2018) The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 19:9–31. https://doi.org/10.1038/s41568-018-0081-9CrossRef

26.

Dudley JC, Lin MT, Le DT, Eshleman JR (2016) Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 22:813–820. https://doi.org/10.1158/1078-0432.CCR-15-1678CrossRefPubMed

27.

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520. https://doi.org/10.1056/NEJMoa1500596CrossRefPubMedPubMedCentral

28.

Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA (2020) Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 10:1808–1825. https://doi.org/10.1158/2159-8290.CD-20-0522CrossRefPubMedPubMedCentral

29.

Jardim DL, Goodman A, de Melo GD, Kurzrock R (2020) The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.10.001CrossRefPubMedPubMedCentral

30.

McGranahan N, Rosenthal R, Hiley CT et al (2017) Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 171:1259–71.e11. https://doi.org/10.1016/j.cell.2017.10.001CrossRefPubMedPubMedCentral

31.

Beer DG, Kardia SL, Huang CC et al (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816–824. https://doi.org/10.1038/nm733CrossRefPubMed

32.

Director’s Challenge Consortium for the Molecular Classification of Lung A, Shedden K, Taylor JM et al (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822–827. https://doi.org/10.1038/nm.1790CrossRef

33.

Wistuba II, Behrens C, Lombardi F et al (2013) Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 19:6261–6271. https://doi.org/10.1158/1078-0432.CCR-13-0596CrossRefPubMed

34.

Chen HY, Yu SL, Chen CH et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11–20. https://doi.org/10.1056/NEJMoa060096CrossRefPubMed

35.

Kratz JR, He J, Van Den Eeden SK et al (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. The Lancet 379:823–832. https://doi.org/10.1016/s0140-6736(11)61941-7CrossRef

36.

Slack FJ, Chinnaiyan AM (2019) The role of non-coding RNAs in oncology. Cell 179:1033–1055. https://doi.org/10.1016/j.cell.2019.10.017CrossRefPubMedPubMedCentral

37.

Li LQ, Zhang LH, Zhang Y et al (2020) Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. Aging (Albany NY) 12:22906–22926. https://doi.org/10.18632/aging.104017CrossRef

38.

Zhao E, Zhou C, Chen S (2020) A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer. Clin Transl Oncol. https://doi.org/10.1007/s12094-020-02414-7CrossRefPubMed

39.

Jiang P, Li Y, Xu Z, He S (2021) A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients. Transl Oncol 14:100924. https://doi.org/10.1016/j.tranon.2020.100924CrossRefPubMed

40.

Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717–734. https://doi.org/10.1038/nrclinonc.2017.101CrossRefPubMed

41.

Brambilla E, Le Teuff G, Marguet S et al (2016) Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol 34:1223–1230. https://doi.org/10.1200/JCO.2015.63.0970CrossRefPubMedPubMedCentral

42.

Reynders K, De Ruysscher D (2016) Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. J Thorac Dis 8:E833–E835. https://doi.org/10.21037/jtd.2016.07.75CrossRefPubMedPubMedCentral

43.

Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K (2010) Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 5:585–590. https://doi.org/10.1097/JTO.0b013e3181d60fd7CrossRefPubMed

44.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol Off J Eur Soc Med Oncol 30:44–56. https://doi.org/10.1093/annonc/mdy495CrossRef

45.

Rizvi H, Sanchez-Vega F, La K et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36:633–641. https://doi.org/10.1200/jco.2017.75.3384CrossRefPubMedPubMedCentral

46.

Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413. https://doi.org/10.1126/science.aan6733CrossRefPubMedPubMedCentral

Titel: Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma
verfasst von: Kui Cao
Mingdong Liu
Keru Ma
Xiangyu Jiang
Jianqun Ma
Jinhong Zhu
Publikationsdatum: 15.10.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 6/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-03069-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma

Abstract

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Cyclic sulfur compounds targeting macrophage polarization into M2/protumor phenotype and their anti-tumor effects

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer

Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing

CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein–Barr virus genes

Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Update Onkologie